A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Abstract
See manuscript- over 250 word count at reviewer's request. Additional word count was approved by Cara Vandy.